Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.

N/AUnknownNCT01679847

Dalian Holley Kingkong Pharmaceutical Co., Ltd8 enrolled

Overview

The purpose of this study is to elucidate the pharmacokinetics and the blood-brain barrier penetration of the elemene.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cancer

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * histopathological or cytopathology diagnosis of malignancy * heart, liver and renal function is normal * Expected survival time is more than 3 months * Signed informed consent exclusion Criteria: * non cancer patient * accepted elemene administration in 1 month * Expected survival time is less than 3 months * no Signed informed consent * heart, liver and renal function is abnormal

Locations (1)

Huashan Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

blood and cerebrospinal fluid concentration

Time frame: 0，0.25，0.5，1，1.5，2，3，3.5，4，6，8，12 hours post dose

Central Contacts

ZHAN QIONG, MD

CONTACT

8621-52887162 zjoan2121@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.